BIVIBIOVIE INC.

Nasdaq bioviepharma.com


$ 3.50 $ 0.08 (2.39 %)    

Wednesday, 21-Aug-2024 15:39:08 EDT
QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 3.4197
$ 3.40 x 200
-- x --
-- - --
$ 2.07 - $ 58.20
108,860
na
12.08M
$ 8.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-12-2024 12-31-2023 10-Q
3 11-08-2023 09-30-2023 10-Q
4 08-16-2023 06-30-2023 10-K
5 05-12-2023 03-31-2023 10-Q
6 02-10-2023 12-31-2022 10-Q
7 11-04-2022 09-30-2022 10-Q
8 09-27-2022 06-30-2022 10-K
9 05-11-2022 03-31-2022 10-Q
10 02-08-2022 12-31-2021 10-Q
11 11-10-2021 09-30-2021 10-Q
12 08-30-2021 06-30-2021 10-K
13 05-10-2021 03-31-2021 10-Q
14 01-29-2021 12-31-2020 10-Q
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-K
17 05-13-2020 03-31-2020 10-Q
18 02-13-2020 12-31-2019 10-Q
19 11-19-2019 09-30-2019 10-Q
20 09-27-2019 06-30-2019 10-K
21 05-10-2019 03-31-2019 10-Q
22 02-12-2019 12-31-2018 10-Q
23 11-14-2018 09-30-2018 10-Q
24 10-05-2018 06-30-2018 10-K
25 05-14-2018 03-31-2018 10-Q
26 02-14-2018 12-31-2017 10-Q
27 11-08-2017 09-30-2017 10-Q
28 08-24-2017 06-30-2017 10-K
29 05-09-2017 03-31-2017 10-Q
30 02-07-2017 12-31-2016 10-Q
31 11-16-2016 09-30-2016 10-Q
32 09-28-2016 06-30-2016 10-K
33 05-23-2016 03-31-2016 10-Q
34 02-16-2016 12-31-2015 10-Q
35 11-13-2015 09-30-2015 10-Q
36 10-01-2015 06-30-2015 10-K
37 05-11-2015 03-31-2015 10-Q
38 02-05-2015 12-31-2014 10-Q
39 11-13-2014 09-30-2014 10-Q
40 09-24-2014 06-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biovie-presents-overview-of-bezisterim-clinical-data-on-longevity-at-11th-aging-research-and-drug-discovery-meeting

BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug ther...

 biovie-achieved-alignment-with-the-fda-on-its-upcoming-sunrise-pd-trial-in-parkinsons-disease-as-a-result-the-company-is-conducting-trial-start-up-activities-with-a-view-to-initiate-patient-screening-in-q4-2024

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's d...

 biovie-announces-1-for-10-reverse-stock-split-now-effective

Common Stock Trading On Split-Adjusted Basis Under Symbol "BIVI" With New CUSIP 09074F405

 thinkequity-initiates-coverage-on-biovie-with-buy-rating-announces-price-target-of-3

ThinkEquity analyst Ashok Kumar initiates coverage on BioVie (NASDAQ:BIVI) with a Buy rating and announces Price Target of $3.

 biovie-presents-protocol-design-of-upcoming-sunrise-pd-phase-2-trial-of-bezisterim-in-patients-with-early-parkinsons-disease-at-atmrd-2024

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's d...

 biovies-bezisterim-full-dataset-from-phase-2a-trial-in-parkinsons-disease-patients-experienced-significant-improvements-in-both-non-motor-symptoms-and-motor-control-while-placebo-treated-patients-worsened

Full Dataset from Phase 2a trial in Parkinson's Disease suggest patients treated with bezisterim experienced significant im...

 biovie-presents-data-showing-potential-for-bezisterim-to-reduce-inflammation-and-restore-homeostasis-in-a-manner-correlated-with-alzheimers-disease-and-biomarker-endpoints

"Bezisterim" has been approved as the non-proprietary name for NE3107 Data shows how bezisterim may be restoring homeos...

 biovie-to-present-data-showing-how-ne3107-potentially-restores-homeostasis-via-specific-genes-associated-with-dementia-metabolism-and-inflammation

BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug the...

 crude-oil-down-over-1-quoin-pharmaceuticals-shares-spike-higher

U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to ...

 why-bitdeer-technologies-shares-are-trading-higher-by-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION